Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Contact us

07 3737 4500

PO Box 3787

South Brisbane QLD 4101

78278343PCR1003

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer

Older couple walking on beach with arms around each other | Icon Cancer Centre
Open for recruitment

Trial summary

The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of JNJ-78278343 and combination agent in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of JNJ-78278343 with the combination agent in Part 2 (dose expansion).

Trial details

Short title

78278343PCR1003

Diagnosis

Prostate cancer

Type of treatment

Medical Oncology

Phase

I

Locations

Investigators

Principal Investigators

Who can participate

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your healthcare provider if you are interested in this clinical trial.